- Home
- ACRS vs SRV Comparison
ACRS vs SRV Comparison
Compare ACRS & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- SRV
- Stock Information
- Founded
- ACRS 2012
- SRV 2007
- Country
- ACRS United States
- SRV United States
- Employees
- ACRS N/A
- SRV N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- SRV Finance Companies
- Sector
- ACRS Health Care
- SRV Finance
- Exchange
- ACRS Nasdaq
- SRV Nasdaq
- Market Cap
- ACRS 165.7M
- SRV 178.7M
- IPO Year
- ACRS 2015
- SRV N/A
- Fundamental
- Price
- ACRS $1.45
- SRV $41.81
- Analyst Decision
- ACRS Strong Buy
- SRV
- Analyst Count
- ACRS 8
- SRV 0
- Target Price
- ACRS $9.71
- SRV N/A
- AVG Volume (30 Days)
- ACRS 755.2K
- SRV 33.9K
- Earning Date
- ACRS 08-06-2025
- SRV 01-01-0001
- Dividend Yield
- ACRS N/A
- SRV 13.38%
- EPS Growth
- ACRS N/A
- SRV N/A
- EPS
- ACRS N/A
- SRV N/A
- Revenue
- ACRS $17,777,000.00
- SRV N/A
- Revenue This Year
- ACRS N/A
- SRV N/A
- Revenue Next Year
- ACRS $11.77
- SRV N/A
- P/E Ratio
- ACRS N/A
- SRV N/A
- Revenue Growth
- ACRS N/A
- SRV N/A
- 52 Week Low
- ACRS $1.05
- SRV $30.73
- 52 Week High
- ACRS $5.17
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- ACRS 51.96
- SRV 55.07
- Support Level
- ACRS $1.37
- SRV $41.50
- Resistance Level
- ACRS $1.59
- SRV $42.77
- Average True Range (ATR)
- ACRS 0.10
- SRV 0.59
- MACD
- ACRS -0.01
- SRV 0.01
- Stochastic Oscillator
- ACRS 28.57
- SRV 61.01
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.